NCT04989335View on ClinicalTrials.gov

Bisantrene Combination for Resistant AML

PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 2, 2021

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2025

Conditions
Myelogenous Leukemia, Acute
Interventions
DRUG

Bisantrene

Combined escalated dose chemotherapy

DRUG

Fludarabine

Combined escalated dose chemotherapy

DRUG

Clofarabine

Combined escalated dose chemotherapy

Trial Locations (1)

57261

RECRUITING

Chaim Sheba Medical Center, Ramat Gan

All Listed Sponsors
collaborator

Race Oncology Ltd

INDUSTRY

lead

Sheba Medical Center

OTHER_GOV